Please Wait
Applying Filters...
menu
    • menu
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Brepocitinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Priovant's Brepocitinib Nda For Dermatomyositis Accepted By FDA
    Priovant's Brepocitinib Nda For Dermatomyositis Accepted By FDA

    03 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/03/3248199/34323/en/Priovant-Announces-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-Brepocitinib-in-Dermatomyositis.html

    GLOBENEWSWIRE
    03 Mar 2026
    Share Share
    Priovant Reports Positive Phase 2 Data For Brepocitinib
    Priovant Reports Positive Phase 2 Data For Brepocitinib

    06 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/06/3233726/34323/en/Priovant-Announces-Positive-Phase-2-Results-for-Brepocitinib-in-Cutaneous-Sarcoidosis-CS.html

    GLOBENEWSWIRE
    06 Feb 2026
    Share Share
    Priovant Advances Brepocitinib To Phase 3 In Skin Disease Study
    Priovant Advances Brepocitinib To Phase 3 In Skin Disease Study

    06 Feb 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/priovant-plots-path-to-phase-3-as-brepocitinib-clears-mid-stage-skin-disease-study

    BIOSPACE
    06 Feb 2026
    Share Share
    Roivant Reports Positive Phase 2 Data For Brepocitinib
    Roivant Reports Positive Phase 2 Data For Brepocitinib

    06 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/06/3233728/34323/en/Roivant-Announces-Positive-Phase-2-Results-for-Brepocitinib-in-Cutaneous-Sarcoidosis-CS-and-Reports-Financial-Results-for-the-Third-Quarter-Ended-December-31-2025.html

    GLOBENEWSWIRE
    06 Feb 2026
    Share Share
    Priovant Will Move Brepocitinib To Phase 3 After Midstage Win
    Priovant Will Move Brepocitinib To Phase 3 After Midstage Win

    06 Feb 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/pfizer-backed-priovant-scores-again-fast-rising-brepocitinib-mid-stage-study

    FIERCE BIOTECH
    06 Feb 2026
    Share Share
    Roivant Highlights Progress and Outlook at Its 2025 Investor Day
    Roivant Highlights Progress and Outlook at Its 2025 Investor Day

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3203811/34323/en/Roivant-Highlights-Continued-Pipeline-Progress-and-Outlook-for-Company-s-Next-Phase-of-Growth-at-2025-Investor-Day.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.